Wednesday, August 26, 2026

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

95% Accuracy, 0.1% False Alarms: AI Fire Detection Is Getting Real

The worst wildfire in South Korea's history has prompted tech firms to develop AI solutions for early detection and response.

Korean Coast Guard Cracks Down on Chinese Fishing Boats

Chinese fishing boats the South Korean Coast...

Tag: NRAS mutations

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Belvarafenib: The Promising New Targeted Cancer Drug for NRAS Mutant Melanoma

Hanmi Pharmaceutical presents Belvarafenib's phase 2 trial for NRAS mutant melanoma at KCA 2026, targeting unmet medical needs.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.